

# Dong Wu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9583633/publications.pdf>

Version: 2024-02-01

30  
papers

1,281  
citations

567281

15  
h-index

501196

28  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1250  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma. <i>Molecular Cancer</i> , 2020, 19, 110.	19.2	295
2	Circular RNA circTRIM33 acts as the sponge of MicroRNA-191 to suppress hepatocellular carcinoma progression. <i>Molecular Cancer</i> , 2019, 18, 105.	19.2	172
3	Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis. <i>Molecular Cancer</i> , 2020, 19, 92.	19.2	147
4	Downregulation of RNF128 activates Wnt/ $\beta$ -catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 21.	17.0	99
5	Current applications and future perspective of CRISPR/Cas9 gene editing in cancer. <i>Molecular Cancer</i> , 2022, 21, 57.	19.2	85
6	Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 200.	17.0	68
7	Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors. <i>Theranostics</i> , 2019, 9, 4678-4687.	10.0	61
8	The long noncoding RNA NORAD enhances the TGF $\beta$ 2 pathway to promote hepatocellular carcinoma progression by targeting miR-2025p. <i>Journal of Cellular Physiology</i> , 2019, 234, 12051-12060.	4.1	44
9	Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. <i>Biomarker Research</i> , 2021, 9, 19.	6.8	43
10	Overexpression of RNF38 facilitates TGF- $\beta$ 2 signaling by Ubiquitinating and degrading AHNAK in hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 113.	8.6	41
11	Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma. <i>Cell Death and Disease</i> , 2017, 8, 3205.	6.3	34
12	Liver Computed Tomographic Perfusion in the Assessment of Microvascular Invasion in Patients With Small Hepatocellular Carcinoma. <i>Investigative Radiology</i> , 2015, 50, 188-194.	6.2	33
13	Lymphoid-specific helicase promotes the growth and invasion of hepatocellular carcinoma by transcriptional regulation of centromere protein F expression. <i>Cancer Science</i> , 2019, 110, 2133-2144.	3.9	25
14	Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Anti-Programmed Death 1 Immunotherapy for Recurrent Liver Tumors. <i>Liver Transplantation</i> , 2021, 27, 444-449.	2.4	24
15	CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 705378.	4.8	17
16	Value of CT-guided Core Needle Biopsy in Diagnosing Spinal Lesions: A Comparison Study. <i>Orthopaedic Surgery</i> , 2019, 11, 60-65.	1.8	16
17	Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 4094-4094.	1.6	14
18	Mortalin stabilizes CD151-dependent tetraspanin-enriched microdomains and implicates in the progression of hepatocellular carcinoma. <i>Journal of Cancer</i> , 2019, 10, 6199-6206.	2.5	11

#	ARTICLE	IF	CITATIONS
19	Simulation of portal/hepatic vein associated remnant liver ischemia/congestion by three-dimensional visualization technology based on preoperative CT scan. <i>Annals of Translational Medicine</i> , 2021, 9, 756-756.	1.7	8
20	MRI-based Nomogram Predicts the Risk of Progression of Unresectable Hepatocellular Carcinoma After Combined Lenvatinib and anti-PD-1 Antibody Therapy. <i>Academic Radiology</i> , 2022, 29, 819-829.	2.5	8
21	Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4099-4099.	1.6	6
22	Application of Thermal Insulation Gunite Material to the High Geo-Temperature Roadway. <i>Advances in Civil Engineering</i> , 2020, 2020, 1-12.	0.7	5
23	RAF1 expression is correlated with HAF, a parameter of liver computed tomographic perfusion, and may predict the early therapeutic response to sorafenib in advanced hepatocellular carcinoma patients. <i>Open Medicine (Poland)</i> , 2020, 15, 167-174.	1.3	5
24	Phase II study of lenvatinib in combination with GEMOX chemotherapy for advanced intrahepatic cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16163-e16163.	1.6	5
25	Liver computed tomographic perfusion for monitoring the early therapeutic response to sorafenib in advanced hepatocellular carcinoma patients. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 1556.	0.9	5
26	Apparent Diffusion Coefficient <scp>MRI</scp> Shows Association With Early Progression of Unresectable Intrahepatic Cholangiocarcinoma With Combined Targetedâ€mmunotherapy. <i>Journal of Magnetic Resonance Imaging</i> , 2023, 57, 275-284.	3.4	5
27	Contrast-enhanced MRI could predict response of systemic therapy in advanced intrahepatic cholangiocarcinoma. <i>European Radiology</i> , 2022, 32, 5156-5165.	4.5	4
28	Radiological response as a predictor of pathological response to combined tyrosine kinase inhibitor (TKI) and anti-PD-1 antibodies in hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, e16144-e16144.	1.6	1
29	Future liver volume combined with platelet count predicts liver failure after major hepatectomy. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2022, , .	1.8	0
30	KSR2-14â€3-31¶ complex serves as a biomarker and potential therapeutic target in sorafenib-resistant hepatocellular carcinoma. <i>Biomarker Research</i> , 2022, 10, 25.	6.8	0